Lung Cancer - Non-Small Cell News

CancerConsultants provides summaries of new treatment strategies as they are discovered and reported by cancer physicians around the world. Our medical staff attends medical meetings worldwide and reviews medical literature daily to ensure appropriate news is provided to cancer patients and their families in a timely manner.

News of the results of recent clinical trials evaluating cancer therapies and supportive care strategies serve to educate patients regarding new treatment strategies for cancer and facilitate discussions with their doctor. Development of new cancer treatments usually begins in patients with recurrent or metastatic cancers. Once the new treatment appears effective, it is applied to earlier stages of the disease or to patients at higher risk of treatment failure.

Share

Lung Cancer - Non-Small Cell News


Pass It On: It’s National Lung Cancer Awareness Month (November 2, 2016)

There are several types of lung cancer: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma and lung carcinoid tumors, with NSCLC and SCLC accounting for about 95% of diagnoses... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of... Continue Reading

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer (October 20, 2016)

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer... Continue Reading

Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues (October 14, 2016)

Voices of Value Speak Up: Non-Small Cell Lung Cancer is the first part of a national six-event program presented by Patients Rising and Aimed Alliance. Where is the patient in the national conversation... Continue Reading

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (September 14, 2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (September 13, 2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors... Continue Reading

Keytruda® Demonstrates Superior Survival Compared to Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer (July 5, 2016)

Teatment with Keytruda® (pembrolizumab) for previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 is superior to standard chemotherapy. Lung cancer... Continue Reading

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials (June 6, 2016)

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising... Continue Reading

More Lung Cancer - Non-Small Cell News

Latest Lung Cancer - Non-Small Cell News By Stage


Screening/Prevention

Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues (October 14, 2016)

Voices of Value Speak Up: Non-Small Cell Lung Cancer is the first part of a national six-event program presented by Patients Rising and Aimed Alliance. Where is the patient in the national conversation about value and our healthcare? It’s muted.... Continue Reading

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make­up or a tumor’s... Continue Reading

16th World Conference on Lung Cancer Expected to Highlight Advances in Precision Medicine (September 6, 2015)

Today, September 6, the 16th World Conference on Lung Cancer (WCLC) begins in Denver, Colorado. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries... Continue Reading

Changing the Face of Lung Cancer: Live Video Chat about Lung Cancer Screening with the Roswell Park Experts (January 21, 2015)

Cancer screening saves lives, but when it comes to lung cancer, early detection has long been a challenge. Thankfully, the outlook for those at highest risk of this deadly disease is improving thanks to new lung cancer screening techniques. Three leading... Continue Reading

Year in Review: Research News from 2014 in Non-Small Cell Lung Cancer (January 9, 2015)

After several years of developments in lung cancer treatment, more-targeted and more-individualized treatment for non–small cell lung cancer became a reality. Results from studies evaluating ALK-inhibitors continued to show promise in 2014 and initial... Continue Reading

More Screening/Prevention Lung Cancer - Non-Small Cell

Stages I-IIIA

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues (October 14, 2016)

Voices of Value Speak Up: Non-Small Cell Lung Cancer is the first part of a national six-event program presented by Patients Rising and Aimed Alliance. Where is the patient in the national conversation about value and our healthcare? It’s muted.... Continue Reading

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make­up or a tumor’s... Continue Reading

16th World Conference on Lung Cancer Expected to Highlight Advances in Precision Medicine (September 6, 2015)

Today, September 6, the 16th World Conference on Lung Cancer (WCLC) begins in Denver, Colorado. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries... Continue Reading

More Stages I-IIIA Lung Cancer - Non-Small Cell

Stages IIIB-IV

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues (October 14, 2016)

Voices of Value Speak Up: Non-Small Cell Lung Cancer is the first part of a national six-event program presented by Patients Rising and Aimed Alliance. Where is the patient in the national conversation about value and our healthcare? It’s muted.... Continue Reading

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (September 14, 2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The FDA’s Breakthrough Therapy Designation... Continue Reading

More Stages IIIB-IV Lung Cancer - Non-Small Cell

Recurrent

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues (October 14, 2016)

Voices of Value Speak Up: Non-Small Cell Lung Cancer is the first part of a national six-event program presented by Patients Rising and Aimed Alliance. Where is the patient in the national conversation about value and our healthcare? It’s muted.... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (September 13, 2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled... Continue Reading

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make­up or a tumor’s... Continue Reading

More Recurrent Lung Cancer - Non-Small Cell

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS